Orion Biotechnology Canada Ltd. is a clinical-stage company that uses a proprietary discovery platform to design highly potent drugs against difficult G-Protein-Coupled Receptor (GPCR) targets. Its lead candidate, OB-002, is a first-in-class chemokine analog that functions as a best-in-class CCR5 antagonist and shows promise across oncology, neuroinflammation, and other serious diseases. The firm collaborates with global institutions and leverages its GPCR expertise to unlock drug targets that have resisted traditional modalities. Current development work focuses on expanding translational research for OB-002, including blood–brain barrier penetration studies. Orion plans to progress OB-002 further into clinical trials while using its platform to generate additional GPCR-focused candidates. Although no revenue or user metrics are disclosed, the company continues to secure non-dilutive and strategic financing to advance its pipeline.

Total raised

$19M

Funding rounds

5

Latest round

Series A

Latest activity

Jun 2021